icon-folder.gif   Conference Reports for NATAP  
 
  EASL - The International Liver Congress 2014
49th Annual Meeting of the European
Association for the Study of the Liver
London, United Kingdom áApril 9-13
Back grey_arrow_rt.gif
 
 
 
Effect of alisporivir (ALV) on the pharmacokinetics (PK), safety, and tolerability of methadone in healthy subjects and opioid-dependent patients on stable methadone maintenance therapy (MMT)
 
 
  Reported by Jules Levin
EASL 2014 April 9-13 London, UK
 
STEVEN J. KOVACS*1, JUNE KE1, AVANTIKA BARVE1, LYNN R. WEBSTER2, YI CHENG3, JIE ZHANG1, ROBERT MAIETTA4, GANGADHAR SUNKARA1, DANIEL S. STEIN1 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (NIBR) 1EAST HANOVER, NJ, USA; 2CRI LIFETREE, SALT LAKE CITY, UT, USA; 3BEIJING NOVARTIS PHARMA CO. LTD, SHANGHAI, CHINA; 4NIBR, CAMBRIDGE, MA, USA
 
Recruiting. This study is currently recruiting participants. Verified April 2014 by Novartis
 
Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Patients Who Have Previously Failed Interferon Therapy or Are Intolerant or Unable to Take Interferon (ALtitude II)
 
Recruiting Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment na´ve Patients

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif